nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-10. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Albert Cardona is a neuroscientist and connectomics researcher who is a Programme Leader at the MRC Laboratory of Molecular Biology. and a Professor at the University of Cambridge in Cambridge, UK. He is also a Fellow at Pembroke College, Cambridge. His research maps neuronal circuits with synaptic resolution using volume electron microscopy, particularly in small animals such as the Drosophila, and studies how the structure of a neural circuit relates to its function
CCPs can be a valuable resource of genetic material. They can be used to preserve valuable genetic diversity for future use, or as base for new breeding programs. Promising plants can be selected and multiplied, generating new varieties. It is legal under EU law to sell and buy seeds from a composite cross population as an experiment in the period between 2014 and 2018. In 2000, with the help of plant breeders and the Organic Research Centre, the scientist Martin Wolfe crossed 20 varieties of wheat (selected for quality and yield) and crossed them to obtain 190 new crosses. These seeds were not further selected and planted, grown, harvested and reseeded together as a population. Martin Wolfe called it YQ, for "yield" and "quality". Wolfe lobbied in Brussels and Westminster to receive an exception to the EU regulations that would allow YQ to be sold. In 2014, it was accepted and since 2017 the YQ seed, officially called the "ORC Wakelyns Population" was the first population wheat to go on sale in Europe.
The Prausnitz–Küstner test (PK test, Prausnitz-Küstner reaction) is an immunologic test formerly used by physicians to determine if a patient has an allergic reaction to a specific antigen. The test has been replaced by the safer skin prick test. The PK test involves transferring serum from the test subject to another healthy person, essentially using the second person as a mixing vessel for antibodies and antigen. This is a pathway for transmission of blood-borne ailments like variant Creutzfeldt–Jakob disease, AIDS, and others, which is why the test is no longer recommended. Or in simple words, a test for the presence of immediate hypersensitivity in humans; test serum from an atopic individual is injected intradermally into a normal subject; the normal subject is challenged 24–48 hours later with the antigen suspected of causing the immediate hypersensitivity reaction in the atopic individual.
Sources: en.wikipedia.org
In 1933, Norway, which occupied part of Eastern Greenland, accepted a ruling of the Permanent Court of International Justice affirming Danish sovereignty over all of Greenland and renounced its claim. The 1953 Constitution of Denmark ended Greenland's status as a colony, integrating it fully into the Danish state as a regular county, as part of decolonization efforts and with the consent of the Greenland Provincial Council. In the 1979 Greenlandic home rule referendum, Denmark granted home rule to Greenland, leading to the establishment of a local government authority with responsibility for local matters, but Greenland remains part of the Kingdom of Denmark, with the central government in Copenhagen solely responsible for defence and foreign policy. As part of the Nordic region and the Kingdom of Denmark, Greenland is an associate member of the Nordic Council. Greenland is one of the Overseas Countries and Territories of the EU. Greenlanders are Danish citizens and therefore also EU citizens. In 2009, Greenland was recognised by the Kingdom of Denmark and under international law as a people entitled to external self-determination. Most political parties in Greenland favour independence from Denmark as a long-term goal, with a draft constitution for an independent Greenlandic state presented by lawmakers in 2023, but the majority does not favour severing ties with Denmark in the short term.
This difference is reflected in their metabolism; M1 macrophages have the unique ability to metabolize arginine to the "killer" molecule nitric oxide, whereas M2 macrophages have the unique ability to metabolize arginine to the "repair" molecule ornithine. However, this dichotomy has been recently questioned as further complexity has been discovered. Macrophages are widely thought of as highly plastic and fluid cells, with a fluctuating phenotype. Human macrophages are about 21 micrometres (0.00083 in) in diameter and are produced by the differentiation of monocytes in tissues. They can be identified using flow cytometry or immunohistochemical staining by their specific expression of proteins such as CD14, CD40, CD11b, CD64, F4/80 (mice)/EMR1 (human), lysozyme M, MAC-1/MAC-3 and CD68. Macrophages were first discovered and named by Élie Metchnikoff, a Russian Empire zoologist, in 1884.
Ptaquiloside is a norsesquiterpene glucoside produced by bracken ferns (majorly Pteridium aquilinum) during metabolism. It is identified to be the main carcinogen of the ferns and to be responsible for their biological effects, such as haemorrhagic disease and bright blindness in livestock and oesophageal, gastric cancer in humans. Ptaquiloside has an unstable chemical structure and acts as a DNA alkylating agent under physiological conditions. It was first isolated and characterized by Yamada and co-workers in 1983. The pure form ptaquiloside is a colorless amorphous compound. It is readily soluble in water and fairly soluble in ethyl acetate. Except in the plants, ptaquiloside has been detected in the milk and meat of affected livestock, as well as in the underground water and dry soil around bracken fern vegetation. The prevalence of ptaquiloside in daily sources along with its carcinogenic effects make it an increasing biological hazard in modern days.
== Intermediates as substrates for biosynthetic processes == In this subheading, as in the previous one, the TCA intermediates are identified by italics. Several of the citric acid cycle intermediates are used for the synthesis of important compounds, which will have significant cataplerotic effects on the cycle. Acetyl-CoA cannot be transported out of the mitochondrion. To obtain cytosolic acetyl-CoA, citrate is removed from the citric acid cycle and carried across the inner mitochondrial membrane into the cytosol. There it is cleaved by ATP citrate lyase into acetyl-CoA and oxaloacetate. The oxaloacetate is returned to mitochondrion as malate (and then converted back into oxaloacetate to transfer more acetyl-CoA out of the mitochondrion). The cytosolic acetyl-CoA is used for fatty acid synthesis and the production of cholesterol. Cholesterol can, in turn, be used to synthesize the steroid hormones, bile salts, and vitamin D. The carbon skeletons of many non-essential amino acids are made from citric acid cycle intermediates. To turn them into amino acids the alpha keto-acids formed from the citric acid cycle intermediates have to acquire their amino groups from glutamate in a transamination reaction, in which pyridoxal phosphate is a cofactor. In this reaction the glutamate is converted into alpha-ketoglutarate, which is a citric acid cycle intermediate. The intermediates that can provide the carbon skeletons for amino acid synthesis are oxaloacetate which forms aspartate and asparagine; and alpha-ketoglutarate which forms glutamine, proline, and arginine.
Sources: en.wikipedia.org
Critics greeted As Good as Dead with generally positive reviews. In a four-star review, AllMusic stated that with As Good as Dead Local H stood apart from other rock bands signed in the wake of Nirvana, noting that in exploring the album's "litany of bitterness over a life that's being wasted before your very eyes," frontman Scott Lucas was one of only a few artists who could approach the "emotional resonance" of Kurt Cobain. Similarly, New Noise Magazine stated in a five-star review that it was a mistake to lump Local H in with other bands signed after grunge had become popular, writing, "As Good As Dead matches the sentiment of the era, but comes from a much more sincere place." Robert Christgau of The Village Voice awarded the album an A− rating and complimented the band for their "isometric power—that sense of tremendous force bravely exerted against implacable reality." Sputnikmusic deemed the album a "wonderful slice of apathy and cynicism that's just as punk-oriented as it is grunge-oriented."
== Comparison == LADA differs from both type 1 and type 2 diabetes. It has a later onset and slower progression than classic type 1 diabetes and is characterized by autoimmune-mediated β-cell destruction, while also exhibiting features of type 2 diabetes due to progressive insulin deficiency over time. Genetic testing can help distinguish LADA from monogenic forms of diabetes (e.g., MODY), which lack autoimmune markers and do not share the same genetic profile.
Leaching involves the use of aqueous solutions to extract metal from metal-bearing materials. The extracting solution is called a lixiviant. The lixiviant is optimized in terms of pH, oxidation-reduction potential, presence of chelating agents, and temperature. In a simple implementation, a slurry of the pulverized ore in the lixiviant solution is filtered to yield a solution containing the metal ion(s) of interest. For example copper in its carbonate minerals such as malachite dissolve in aqueous sulfuric acid. On the other hand, copper sulfide minerals, which are more prevalent, are not amenable to hydrometallurgy, at least until they have been roasted. Hydrometallurgy is used to extract rare earths. By using chelating agents, one can selectively extract certain metals.. Some leaching reactor configurations are in-situ, heap, vat leaching, tank, and autoclave. In-situ leaching is also called "solution mining" involves pumped extracting solution into the deposit. The Beverley uranium deposit is an example of in-situ leaching. In heap leaching, crushed (and sometimes agglomerated) ore is piled in a heap on top of an impervious sheet. Leach solution is sprayed over the top of the heap and allowed to percolate downward through the heap. The heap design usually incorporates collection sumps, which allow the "pregnant" leach solution (i.e. solution with dissolved valuable metals) to be pumped for further processing.
After tracing the adaptation strategy of the party, he found confirming evidence for five of the factors contributing to its electoral success, already mentioned in the theoretical literature on former Marxist–Leninist parties, namely the economic situation, the weakness of the opponents, the electoral laws, the fragmentation of the political spectrum and the legacy of the old regime. However, Marandici identified seven additional explanatory factors at work in the Moldovan case, namely the foreign support for certain political parties, separatism, the appeal to the ethnic minorities, the alliance-building capacity, the reliance on the Soviet notion of the Moldovan identity, the state-building process and the control over a significant portion of the media. It is due to these seven additional factors that the party managed to consolidate and expand its constituency. In the post-Soviet states, the Party of Communists are the only ones who have been in power for so long and did not change the name of the party. In Asia, a number of Marxist–Leninist regimes and movements continue to exist. The People's Republic of China has continued the agenda of Deng Xiaoping's 1980s reforms by initiating significant privatisation of the national economy. At the same time, no corresponding political liberalisation has occurred as happened in previous years to Eastern European countries.
=== Wort cooling === After the whirlpool, the wort is cooled to the appropriate fermentation temperature before being transferred to the fermentation area. In modern breweries this is achieved through a plate heat exchanger. A plate heat exchanger has several ridged plates, which form two separate paths. The wort is pumped into the heat exchanger and goes through every other gap between the plates. The cooling medium, usually water from a cold liquor tank, goes through the other gaps. The ridges in the plates ensure turbulent flow. Wort is typically cooled in a plate heat exchanger from near boiling point to the appropriate pitching temperature. Cooling may use a single-stage system with chilled water, or a multi-stage system using water followed by a secondary coolant such as glycol. After cooling, the wort is oxygenated before fermentation to provide oxygen required for yeast development. While boiling, it is useful to recover some of the energy used to boil the wort. On its way out of the brewery, the steam created during the boil is passed over a coil through which unheated water flows. By adjusting the rate of flow, the output temperature of the water can be controlled. This is also often done using a plate heat exchanger. The water is then stored for later use in the next mash, in equipment cleaning, or wherever necessary. Another common method of energy recovery takes place during the wort cooling. When cold water is used to cool the wort in a heat exchanger, the water is significantly warmed.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.